Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kirk Geter

Podiatrist Washington, DC Doctor of Podiatric Medicine

NPI 1689756884 CMS profile 76685

2041 Gerogia Ave Nw, Washington, DC 20060

Open in the dashboard

General payments

$1,370

48 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kirk Geter of Washington, DC is reported in the CMS Open Payments database as having received $1,370 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $514 11
2024 General $193 7
2023 General $205 10
2022 General $271 11
2021 General $129 6
2020 General $41 2
2019 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirk Geter
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Kirk Geter were reported at $514. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Kirk Geter Podiatrist median Middle half National median
2019 $18 $196 $72–$601 $163
2020 $41 $118 $38–$335 $114
2021 $129 $169 $57–$573 $132
2022 $271 $220 $74–$782 $149
2023 $205 $208 $71–$635 $160
2024 $193 $237 $87–$681 $164
2025 $514 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $796 24 payments
  2. Integra LifeSciences Corporation $175 8 payments
  3. Kerecis Limited $149 4 payments
  4. Medtronic, Inc. $61 3 payments
  5. PolyNovo North America LLC $60 2 payments
  6. W. L. Gore & Associates, Inc. $41 2 payments
  7. Tactile Systems Technology Inc $22 1 payment
  8. Avita Medical Americas, LLC $19 1 payment
  9. Allergan Inc. $19 1 payment
  10. Musculoskeletal Transplant Foundation Inc. $15 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,370 48 payments
Products named General payments · program years 2019–2025
  1. STRAVIX PL $368 5 payments
  2. GRAFIX PL $189 7 payments
  3. Kerecis Omega3 SurgiClose $122 3 payments
  4. Kerecis Omega3 Marigen $122 3 payments
  5. Integra Recon-Skin And Wound $120 6 payments
  6. Integra Recon-Skin And Wound $120 6 payments
  7. INTEGRA DERMAL REGENERATION TEMPLATE $120 6 payments
  8. STRAVIX $106 4 payments
  9. COLLAGENASE SANTYL $104 5 payments
  10. SURGIMEND $102 5 payments
  11. Other $1,221 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

509

Median for Podiatry: 160

Drug cost

$13,845

Median for Podiatry: $2,368

Branded share of claims

12.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clotrimazole Generic 317 $8,219
Ammonium Lactate Generic 65 $1,772
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 48 $1,534
Fluocinonide Generic 22 $882
Ciclopirox Ciclopirox Olamine Brand 17 $520
Ciclopirox Generic 14 $486
Nystatin Generic 26 $433

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$36,359

Medicare's payments for the services billed

Medicare patients

265

Average age 72

Services billed

539

153 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Arthritis 40%
Chronic kidney disease 35%
Ischemic heart disease 22%
Cancer 16%
Depression 15%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record